Longevity
Investors
Conference

September 28-30, 2022

In-person conference

 

Gstaad, Switzerland

Calender.png
asd.png
Untitled-3.png
  • LinkedIn
  • Twitter
  • Instagram

About the conference 

The Longevity Investors Conference is the world’s leading and most private longevity-focus investors only conference.

LIC provides relevant insights into the longevity subject, expert education, investment opportunities, excellent networking opportunities and a great setting in an exclusive location.

The two full days conference is bringing together the world’s top longevity KOLs, institutional and private investors, wealthy private investors, family offices and funds.

What is Longevity?

Longevity is the science of anti-aging research and rejuvenation.

 

It has experienced an unprecedented advance over recent years, particularly with the discovery that the rate of aging is controlled, at least to some extent, by genetic pathways and biochemical processes.

Longevity identifies both lifestyle and pharmaceutical targets to improve the human health-span (i.e.the time we can live without any negative impact from aging.)

Longevity will be one of the largest, if not the largest, investment opportunity in the decades to come.

 

Why join the LIC?

  • High Quality Networking: The LIC is not a mass event.The number of participants is limited to 150, which ensures a private atmosphere in a beautiful setting. Investors can meet other investors as well as leading longevity experts and KOLs.

  • Personal knowledge transfer from best-in-field industry and academic speakers

  • Learn first-hand about attractive investment and business opportunities in the longevity space.

  • Establish strategic partnerships with other business leaders in one of a kind setting in 5*hotel in Gstaad, one of the most exclusive Swiss mountain resorts.

  • Get acquainted and experience with the latest trends related to personal longevity (supplements, therapies, and many more).

Screenshot 2022-02-17 at 17.59.25.png

Investors

Screenshot 2022-02-17 at 17.59.34.png

C-level Executives

Screenshot 2022-02-17 at 17.59.41.png

Academia

Screenshot 2022-02-17 at 17.58.35.png

30+

Outstanding Speakers

Screenshot 2022-02-17 at 17.58.42.png

100-150

Hand-picked delegates

Screenshot 2022-02-17 at 17.59.02.png

2 full-days

Conference

Packages

DELUXE ROOM

DELUXE ROOM

Package with accommodation

Price: Sold out

Includes:

  • 2-nights stay in a Chic room at Le Grand Bellevue 

  • 2 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking dinner on Wednesday evening 

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

 

The package does NOT include:

  • Travel service to and from Gstaad

SUITE

SUITE

Package with accommodation

Price:         Sold out

Includes:

  • 2-nights stay in a Deluxe room at Le Grand Bellevue

  • 2 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking dinner on Wednesday evening

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

 

The package does NOT include:

  • Travel service to and from Gstaad

CONFERENCE-ONLY

CONFERENCE ONLY

Package without accommodation

Price:         3500 CHF

Late Bird Price: 4200 CHF

Includes:

​​​

  • 2 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking "flying-dinner" on Wednesday evening 

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

The package does NOT include:

  • Travel service to and from Gstaad

  • Accommodation

*We have preferential rates with Le Grand Bellevue should you wish to extend your stay.

We are happy to support you with accommodation and travel service arrangements.

Please contact info@longevityinvestors.ch for more information.

 

Speakers 

We have the honor of welcoming the leading longevity industry experts and scientists at the conference

More to be announced

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Kristen Fortney

CEO and Co-Founder, BioAge

Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology
company developing a pipeline of treatments to extend healthy lifespan by targeting the
molecular causes of aging. The company uses its discovery platform, which combines
quantitative analysis of proprietary longitudinal human samples with detailed health
records tracking individuals over the lifespan, to map out the key molecular pathways
that impact healthy human aging. By targeting these pathways with a large and
mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or
even prevent diseases of aging in entirely new ways.

Kristen’s scientific background is in aging biology and bioinformatics. She received her
PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral
training at Stanford University where she was a fellow of the Ellison Medical Foundation
/ American Federation for Aging Research.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

George Church

Professor of Genetics, Harvard Medical School

George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

George leads Synthetic Biology at the Wyss Institute and is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Nir Barzilai

Director, Institute for Aging Research, Albert Einstein College of Medicine

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.

He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.

Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Aubrey de Grey

Dr. Aubrey de Grey is an English author and biomedical gerontologist. He is the author of The Mitochondrial Free Radical Theory of Aging and co-author of Ending Aging. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Ageing Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives talks at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Brian Kennedy

Director, Centre for Healthy Longevity and Professor Departments of Biochemistry and Physiology, National University of Singapore

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Program, and (3) the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality.

Dr. Kennedy has adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Eric Verdin

President & CEO, Buck Institute for Research on Aging

Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Ageing. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).​

Dr. Verdin studies how metabolism, diet, and small molecules impact epigenetic regulatory mechanisms, and thereby the ageing process and its associated diseases. He is a highly cited scientist (top 1 percent) and has been recognized for his research with multiple awards including a fellowship from the American Association for the Advancement of Science, election to the American Society for Clinical Investigation, the Association of American Physicians, and Belgium’s Royal Academy of Medicine.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Christian Angermayer

Founder at Apeiron Investment Group

Christian Angermayer is a serial entrepreneur, investor and visionary who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives.

Christian’s family office and private investment company, Apeiron Investment Group has more than USD 3.5 billion under management and 60 people across five international locations. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Entertainment, Leisure & Hospitality. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns. His current areas of focus include: psychedelics and mental health, longevity, crypto and future tech.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Michael Greve

Founder at Forever Healthy Foundation

Michael Greve is the founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures.

With his own team, he produces scientific papers that can be thought of as a screenshot of current world knowledge on a topic - each paper based on about 2000 abstracts and 150 studies. He publishes them in a database on his website, freely accessible to anyone at any time, comprehensively transformed into practical advice.

He has turned himself into the leading global figure of a new approach to longevity: he talks about rejuvenation, the preservation and restoration of youth. He talks about viewing the process of aging as a treatable disease, not an inescapable fate. All this not with the goal of eternal life, but of prolonging the healthy life span as much as possible.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Manuel Blanco

Managing Director and Head Market Area Gstaad International and Bern, Credit Suisse

As Market Head of the international location Gstaad and Member of the Management Committee Private Banking Region Mittelland, Manuel Blanco runs a team of banking industry professionals with focus onto entrepreneurs, impact investors, global families and wealthy individuals.

In his 28 years of industry experience he was responsible for the Executive & Entrepreneurs Desk for Germany International & Domestic within the UHNW Wealth Management International Division. Later he became responsible for the Business Development & Growth of the Spanish market. By collaborating cross-divisional he could gain enhanced investment management skills and offer Investment Banking deal-flow to Semi-Institutional clients with a holistic advisory approach. During this time he was in management positions as well as specialist position. Manuel Blanco graduated with a Master Degree in Science of Wealth Management of the University of Rochester (NY) and with
a Master in Advanced Science of Finance of the University of Bern (Switzerland) in 2018.

As a pan-european person he owns a Swiss and a Spanish citizenship. Manuel Blanco is married, he is father of 3 children and he lives in Switzerland. As Founder of the Impact Summit Gstaad Association he enables Investors to access globally ESG conform Investments. He is a board member of the Official Spanish-Swiss Chamber of Commerce and of a local Swiss soccer club and he is a member of the Swiss German Parliament Friendship-Club. In his leisure time he is interested in geo-politics, ESG, soccer, skiing and music.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Simone Gibertoni

CEO, Clinique La Prairie

Simone is CEO of Clinique La Prairie, one of the most iconic Swiss brands, where he is driving its international development and its diversification strategy, with the mission of creating a global player able to help people live a longer, healthier and better life.

Simone is CEO and co-founder of Clinique La Prairie Holistic Health, a leading ultraluxury company in “Longevity Supplements”.

Simone serves on the board of various companies in the field of Cosmetics, Health and Genetics. He writes and teaches (in business school and universities) about marketing, brand building, strategy, and organisational subjects.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Miri Polachek

General Partner, quadraScope

Miri Polachek is an entrepreneurial executive and investor with over 25 years’ experience in the healthcare industry. She is currently General Partner at a newly formed venture capital fund investing in rejuvenation medicine. Until recently, Miri served as CEO of Joy Ventures, a venture builder and fund in the consumer mental health and wellbeing domain.

Miri co-founded and led Israel Brain Technologies, which served as a hub and catalyst for braintech innovation and commercialization, including the world’s first braintech startup accelerator. Miri has also held financial management positions in leading global healthcare companies including Pfizer and Teva, and was VP Finance at IntegraMed. She holds an MA in Health Economics from Boston University and an MBA from New York University.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Sebastian Pünzeler

Partner, Apollo Health Ventures

Sebastian has more than 10 years of experience in the life science industry, from applied and basic research to venture capital investments and portfolio management. He joined the Apollo Health Ventures investment team as a partner in August 2022 and focuses on venture investing and company building.

Prior to that, Sebastian was an investment professional at coparion, a venture capital firm investing in young German technology startups. In this role he led the life science related investment activities at coparion. His portfolio consisted of pharmaceutical and medical technology companies in various development stages (from concept to clinic), working on different indications and exploiting diverse therapeutic entities. Before joining coparion, Sebastian started his VC career as an analyst intern at Gimv, a European investment company.

Sebastian holds a PhD in molecular biology from the International Max Planck Research School for Molecular Life Sciences (IMPRS-LS) Munich and the LMU Munich Medical Faculty.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Rob Konrad Maciejewski

Co-Founder and CEO, Biolytica

After starting his first company at the age of 15, over the past 20 years Rob has accumulated a broad range of experience in the fields of entrepreneurship, strategic consulting and international management.

After consulting some of the leading health and pharmaceutical companies during his time with one of the BIG4 professional services firms, he served as Head of International Marketing for the leading Swiss retail group with over 25 individual companies, co-founded a software company and was CEO of two renowned companies in the field of International Health Insurance and Health Management.

As a longevity enthusiast and life-long tech geek, he believes the more you know about your body, the more you can improve your health and wellbeing, and is developing solutions and programs to help people do exactly that. Rob also holds a doctorate in Public Healthcare Management.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Elisabeth Roider

Attending Physician, Department of Dermatology, University Hospital of Basel

Elisabeth Roider is a physician scientist, MBA and board-certified dermatologist. She currently works as an attending at the University Hospital of Basel and in a large private office in Zurich, as well as holds a visiting scientist position at the Harvard Medical School in Boston, USA.

Her mission is to use her expertise to identify and solve relevant medical and public health problems and to come up and finally deliver solutions to patients and consumers. In her role as a physician-scientist, she has so far investigated various topics in a highly collaborative and multidisciplinary manner by leading and involving not only clinicians and clinical trial specialists, but also biologists, chemists, machine learning specialists, mathematicians, statisticians, and epidemiologists.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Evelyne Yehudit Bischof

Professor, internal medicine specialist, Longevity physician at Human Longevity Inc.

Prof. Evelyne Bischof is a Chief Physician Associate of Internal Medicine at University Hospital Renji of Jiaotong University Shanghai and concierge longevity physician for executive longevity patients.

Her research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. She published over 80 peer-reviewed papers, is a frequent speaker at scientific and medical conferences in Asia and Europe.

Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc. Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Elena Gross

Founder and CEO, KetoSwiss

Dr. sc. med. Elena Gross is the founder and CEO of KetoSwiss, a Swiss biotech startup, winner of this year's Top 100 Swiss startup public award. KetoSwiss develops highly potent therapeutic ketones for neurological disease prevention.

Elena started her career in academia. She used to be a chronic migraine patient and due to the lack of tolerable and efficacious treatment options, she pursued an MSc in Neuroscience at the University of Oxford. There, she discovered ketone bodies & their potential therapeutic use in neurological disease, which changed her life.

Entrepreneurial in spirit, she is the inventor of two patents. She also initiated & funded the first ever clinical trial using exogenous ketone body salts in the world in her PhD at the University of Basel and University of Harvard Medical School.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Guenther Dobrauz

Partner and Leader, PwC Legal Switzerland

Guenther is a Partner at PwC Zurich and Leader of PwC Legal Switzerland. He is also one of seven members of PwC’s Global Legal Leadership Team and PwC Legal’s Global LegalTech Leader.

He is the author of 10 books mostly on investment law and regulation but also of “Making Money out of Technology”, “Uptake Revisited: How Innovative Products Succeed in International Markets” and “New Suits. Appetite for Disruption in the Legal World”. Guenther is also the host of the educational video series „Appetite for Disruption“, the founder of global technology enthusiasts movement Disruption Disciples, Co-Host of Legal Hackers Zurich, and a permanent member of expert groups at economiesuisse, the Swiss Fund and Asset Management Association and the Swiss Fintech Innovation Association.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Alex Zhavoronkov

Founder and CEO at Insilico Medicine

Alex Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research.

He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative.

He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Wei-Wu He

Executive Chairman, Human Longevity Inc. Chairman and CEO, CASI Pharmaceuticals, Inc. Chairman and founder, Genetron Health.

Dr. Wei-Wu He has been serving as Executive Chairman of Human Longevity Inc. since July 2019. Dr. He is currently the Chairman of CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder of Genetron Health; Dr. He also is the Founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established in 2000.

In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author of more than 50 research publications and inventor of over 32 issued patents. Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Phil Newman

Founder, First Longevity, Editor-in-Chief Longevity.Technology

As Editor-in-Chief of Longevity.Technology Phil oversees daily news and market research to address the crossover between longevity science and investment. This news platform has fast become the #1 for daily news and insights.

As founder of First Longevity Phil and his team help to prepare longevity science and technology businesses for equity funding ahead of introducing deals to, and syndicating deals among, VCs, family offices, and HNWs.

Prior to focusing exclusively on longevity, Phil has applied his marketing and business development expertise at c-level into: IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability markets.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Stephanie Dainow

Executive Director, Lifespan.io

Stephanie Dainow is Executive Director at Lifespan.io [Lifespan Extension Advocacy Foundation], a US based non-profit accelerating biomedical technologies that will increase healthy human lifespan through responsible journalism, research funding, advocacy, education and decentralizing aging research. She is also a Business Mentor to SOSV’s IndieBio venture fund and accelerator, consulting deep tech startup founders on business development and strategy, fundraising and executive leadership.

Previously, Stephanie was with Singularity University in Silicon Valley working across their Innovation Consultancy, Tech Think Tank, University for the Future, and Impact-based Startup Incubator. She also worked for a global management consultancy as a Life Sciences Business Manager and served as Account Director for BioMarin Pharmaceutical. Her early career in NYC spanned global growth for Interpublic Group’s media arm, celebrity and brand marketing, and commercial entertainment.

Stephanie has volunteered around the world and previously held an Advisory Board position at a 501c3 that inspires Harlem youth to pursue STEM careers. She is passionate about empowering leaders to think differently about emerging technologies, disruption, and the future of corporate business.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Lisa Fabiny Kiser

CEO, SENS Research Foundation

Previously serving as SRF’s Executive Director, Lisa worked closely with the organization’s preceding CEO’s for more than a decade, dedicating her expertise towards building all aspects of the organization. With an educational background in Life Sciences and industry experience in microbiology, stem cells, and flow cytometry, Lisa joined SRF in 2010 as a volunteer in the laboratory. She transitioned into organizational administration in early 2012, and with a strong focus on finance and operations advanced into greater roles that balanced the financial, research, educational, and outreach operations of the organization. A Bay Area transplant from the Midwest, she is fully dedicated to advancing rejuvenation biotechnologies and guiding SRF forward as a significant and leading-edge contributor in this rapidly growing field.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Martin Borch Jensen

Co-Founder and CSO, Gordian Biotechnology

Martin Jensen is a CSO at Gordian Biotechnology. He is also the producer of the program at Impetus Grants where he ran the first round of Impetus Grants. His focus is on developing technologies to interrogate the full network of ageing processes inside living organisms. This includes multiplexed measurement of complex states, interpretable perturbations, and context-aware data models.

Previously, he was an academic working on a range of cellular mechanisms involved in ageing: mitochondrial function, NAD metabolism, DNA damage signalling and other stress responses.

Hosts

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Marc P. Bernegger

Founding Partner

Marc P. Bernegger is a serial-tech entrepreneur who has been following developments in the field of longevity since 2009.

Besides co-founding the longevity company-builder Maximon and the Longevity Investors Conference, he is involved in the crypto hedge fund AltAlpha Digital and is among others in the board of CfC St. Moritz and the Swiss Blockchain Federation.

Marc explored Bitcoin in 2012 and was a founding shareholder and board member of Crypto Finance Group (acquired by Deutsche Boerse in 2021).

Marc started his entrepreneurial journey by founding the party platform usgang.ch right after college (acquired by Axel Springer Media). He is also a co-founder of amiando, a ticketing platform, which was purchased by Xing and named “Global Technology Pioneer” by the World Economic Forum (WEF).

Marc holds a master’s degree in law from the University of Zurich and is an alumni of the Singularity University.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Tobias Reichmuth

Founding Partner

Tobias is building companies since he has been 21 years old. He exited his first start-up in 2003, thereafter built Europe’s leading climate-change infrastructure fund SUSI Partners, co-founded Crypto Finance Group and The Singularity Group and has invested in more than 20 start-ups. In 2020 he has launched the Longevity Investors Conference together with Marc P. Bernegger. Tobias is a “lion” at Switzerland’s TV investor-Show “Höhle der Löwen” (Shark-Tank) and aims at a healthy 120 years of life.

 
 

Agenda 2022

More to come...

FIRST DAY - September 28th

8.30 - 9.00

Longevity Workout

Gym

Marie Schmidt

9.00 - 11.00

Welcoming breakfast and free time

Leonard's

11.00 - 11.10

Opening remarks

Conference room

Tobias Reichmuth, Marc P. Bernegger

11.10 - 11.15

Welcome to Gstaad

Conference room

Daniel Koetser

11.15 - 11.35

How to Die Young at a Very Old Age

Conference room

Nir Barzilai

11.35 - 11.55

Rejuvenation biotechnology: a dream whose time has come

Conference room

Aubrey de Grey

11.55 - 12.35

Longevity Industry Overview

Conference room

Brian Kennedy, Martin Jensen, Dina Radenkovic, Nathaniel David, Maria Konovalenko

12.35 - 14.00

Networking Lunch

Leonard's restaurant

14.00 - 14.40

What are the latest discoveries in longevity research?

Yacht Club

TBD

14.40 - 15.00

Aging reversal: Efficient delivery to all cells & affordable to all people

Yacht Club

George Church

15.00 - 15.20

Longevity: the investment opportunity

Yacht Club

Michael Greve

15.20 - 15.40

How to build a longevity company

Yacht Club

Tobias Reichmuth

15.40 - 16.20

Longevity Investment panel

Yacht Club

Joerg Rieker, Miri Polachek, and others

16.20 - 16.40

Coffee Break

Yacht Club




16.40 - 17.00

Fireside chat with Christian Angermayer

Yacht Club

Christian Angermayer

17.00 - 17.20

Longevity Startup scene overview

Yacht Club

Phil Newman


17.20 - 18.00

Startup pitches

Yacht Club

TBD

18.00 - 19.30

Free time/1-1 meetings/Longevity exhibition

Lounge

19.30 - 20.00

Networking reception

Lounge

20.00 - 23.00

Dinner

Leonard's

SECOND DAY - September 29th

8.30 - 9.00

Longevity workout

Gym

Marie Schmidt

9.00 - 10.00

Good morning breakfast

Leonard's

10.00 - 10.30

Trip to mountain location

Mountain location

10.30 - 10.40

Opening remarks

Mountain location

Tobias Reichmuth, Marc P. Bernegger

10.40 - 11.00

One transformative week to live longer, healthier and fuller

Mountain location

Simone Gibertoni

11.00 - 11.40

Longevity supplements overview

Mountain location

Sophie Chabloz, Elena Gross, others

11.40 - 12.00

Longevity programs

Mountain location

Rob Konrad

12.00 - 12.40

Restoring the biological age for an optimal individual performance

Mountain location

Evelyne Bischof, Wei Wu He

12.40 - 14.00

Networking Lunch

Mountain location

14.30 - 14.50

Data and AI application in longevity

Conference room

Alex Zhavoronkov

14.50 - 15.10

Longevity outcome in society: is longevity an opportunity or a burden?

Conference room

Manuel Blanco

15.10 - 15.30

The Effect of Food on Longevity

Conference room

Eric Verdin

15.40 - 16.00

David Sinclair's view on longevity and health

Conference room

David Sinclair

16.00 - 16.40

Crypto meets longevity

Conference room

Guenther Dobrauz, Marc P. Bernegger, others

16.40 - 17.00

TBD

Conference room

TBD

17.00 - 17.40

How to bridge academia and the business

Conference room

Stephanie Dainow, Martin Borch Jensen, Elisabeth Roider

17.40 - 18.00

Maximon Longevity Prize Final

Conference room

TBD

18.00 - 19.30

Free time/1-1 meetings/Longevity exhibition

Lounge

19.30 - 20.00

Networking reception

Yacht Club

20.00 - 23.00

Gala Dinner

Yacht Club

f9672f00-2c21-4c00-a26f-a2d25fa6abaf_edited.jpg

Location: Gstaad

Come up, slow down – the slogan describes what Gstaad is all about.

With its top hotels, gourmet restaurants, luxury chalets and nearby Saanen airport, this traffic-free holiday village is popular with HNWI from all over the world.

Gstaad is hard to beat; it’s a place where guests and locals are in harmony with nature and can enjoy the charms of the surroundings.

 

Venue: Le Grand Bellevue 

LIC is partnering up with one the top luxury hotels in Gstaad: Le Grand Bellevue.

The LIC delegates can enjoy a 2-night stay in a luxurious room or a suite, access to over 3,000 square metres of rejuvenating SPA facilities, and dining experiences in hotel’s gourmet restaurants.

hotel_edited.jpg
 

Sponsors

2560px-Credit_Suisse_Logo.svg.png
clinique-la-prairie-switzerland-logo-0E2CD4C56B-seeklogo.com.png
maximon Logo no background.png
apollo-logo.webp
LOGO.png